News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • U.S. equities are outperforming China due to concentrated AI infrastructure investment.
  • U.S. industrial production is improving, supporting the market's momentum.
  • China's markets remain subdued because of a prolonged property downturn.
  • Potential U.S.-Iran sanctions relief could channel economic gains to the IRGC, raising compliance risk for international firms.
  • Porsche seeks to finalize a second round of employee cost cuts before July factory holidays amid profit pressure.
  • Analysts pitch Tantalus Systems as a discounted smart-grid growth stock after steady contract wins and rising software revenue potential.

Latest Articles

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

Entera Bio Ltd. presented encouraging Phase 1 clinical data at ENDO 2026 demonstrating that their single tablet oral anabolic therapy, EB613, achieved pharmacokinetic and pharmacodynamic profiles comparable to the injectable standard treatment Forteo4. EB613 was well-tolerated with a favorable safety profile and was preferred by study participants…

Novo Nordisk Reclaiming Growth: A Long Trade on GLP-1 Momentum

Novo Nordisk Reclaiming Growth: A Long Trade on GLP-1 Momentum

Novo Nordisk is trading well below its 52-week high despite a dominant position in GLP-1 therapies and fresh regulatory wins for an oral Wegovy tablet. The balance sheet, dividend yield, and a reasonable P/E provide a constructive backdrop. This trade idea proposes a long entry at $44.00 with a $60.00 target over the next 180 trading days and a sto…

BlockchAIn Announces Corporate Name Change to AIB Data Centers Inc.

BlockchAIn Announces Corporate Name Change to AIB Data Centers Inc.

BlockchAIn Digital Infrastructure, trading as AIB on NYSE American, announced a corporate name change to AIB Data Centers Inc. reflecting its strategic pivot from digital asset infrastructure to AI and high-performance computing data center development and operations. The name change will be effective June 25, 2026, with trading under the new name …

Aeries Technology Secures Strategic GCC Advisory Mandate with Leading Global Tax and Financial Advisory Platform

Aeries Technology Secures Strategic GCC Advisory Mandate with Leading Global Tax and Financial Advisory Platform

Aeries Technology has secured a strategic advisory engagement from a leading global tax and financial advisory firm to support the expansion of its India-based Global Capability Center (GCC) in a Tier-II city. This reflects a growing corporate trend of expanding GCCs beyond traditional metro areas to leverage deeper talent pools and improved operat…

QTREX Quantum’s AME Technology Achieves 97% Yield Validation at One of the Largest U.S. Interconnect Manufacturers

QTREX Quantum’s AME Technology Achieves 97% Yield Validation at One of the Largest U.S. Interconnect Manufacturers

QTREX Quantum Ltd. announced a major production milestone as one of the largest U.S.-based interconnect manufacturers adopted QTREX's Additively Manufactured Electronics (AME) technology for full production after extensive validation, achieving a 97% yield rate. This advancement marks QTREX's readiness for demanding manufacturing environments and s…

Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026

Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026

Cadrenal Therapeutics announced plans to initiate a Phase 2a proof-of-concept clinical trial for its drug candidate CAD-1005, targeting prevention of Acute Kidney Injury (AKI) associated with cardiac surgery (CSA-AKI). This expands the potential application of CAD-1005, which is already in late-stage development for heparin-induced thrombocytopenia…

Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing

Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing

Conexeu Sciences Inc., a Nasdaq-listed biotechnology company specializing in regenerative tissue therapies, announced five key leadership appointments including additions to its Board of Directors and the naming of a new Chief Commercial Officer. These leadership enhancements aim to strengthen the company's commercial and strategic capabilities as …

Jet.AI Announces New Record Date for Distribution of SpinCo Shares in Connection with Proposed flyExclusive Transaction

Jet.AI Announces New Record Date for Distribution of SpinCo Shares in Connection with Proposed flyExclusive Transaction

Jet.AI Inc. announced June 25, 2026 as the new record date for stockholders eligible to receive shares of SpinCo in connection with its proposed merger with flyExclusive. The transaction is pending stockholder approval, with the special meeting reconvening on June 23, 2026. Proxy advisory firms recommend voting for the deal, but completion remains …

Alto Ingredients, Inc. Completes Transaction to Monetize All 2025 45Z Clean Fuel Production Tax Credits

Alto Ingredients, Inc. Completes Transaction to Monetize All 2025 45Z Clean Fuel Production Tax Credits

Alto Ingredients, Inc., a US-based producer of specialty alcohols and renewable fuels, completed a sale of its 2025 Section 45Z Clean Fuel Production Tax Credits for approximately $8.9 million in cash. The transaction aligns with the company's strategy to monetize tax credits generated from its low-carbon ethanol production facilities, providing a …

Splash Beverage Group Invests in Avicanna, a Leading Cannabinoid Biopharmaceutical Platform, Advancing Its Transformation Into Cannabinoid Healthcare

Splash Beverage Group Invests in Avicanna, a Leading Cannabinoid Biopharmaceutical Platform, Advancing Its Transformation Into Cannabinoid Healthcare

Splash Beverage Group completed a strategic investment of CDN$300,000 in Avicanna Inc., a leading cannabinoid biopharmaceutical company, to support its shift towards a cannabinoid-based health, wellness, and healthcare platform. The investment aligns with Splash's goal to leverage Avicanna's clinical-stage pharmaceutical assets, intellectual proper…

Patriot Bank Expands High Net Worth Banking Platform in Greenwich, CT

Patriot Bank Expands High Net Worth Banking Platform in Greenwich, CT

Patriot Bank, a subsidiary of Patriot National Bancorp (NASDAQ: PNBK), is expanding its high-net-worth banking platform in Greenwich and Fairfield County, Connecticut. The bank has appointed seasoned private banking executives, including DeWitt Hutchins as Connecticut Market President, and plans to enhance its Mason Street branch with upgraded faci…

RBB Bancorp Announces Authorized Common Stock Repurchase Plan and Partial Redemption of Subordinated Debt

RBB Bancorp Announces Authorized Common Stock Repurchase Plan and Partial Redemption of Subordinated Debt

RBB Bancorp announced that its board authorized a stock repurchase plan to buy back up to 1 million shares, approximately $25 million or 6% of outstanding shares, through June 30, 2028. Concurrently, the company plans to redeem $40 million of its 4.0% Fixed to Floating Rate Subordinated Notes due 2031, reflecting a strong capital position and liqui…

Fate Therapeutics Appoints Laura Hamill to Board of Directors

Fate Therapeutics Appoints Laura Hamill to Board of Directors

Fate Therapeutics appoints Laura Hamill, a seasoned global biopharma executive with extensive commercial and strategic experience, to its Board as it advances its iPSC-derived cellular immunotherapy pipeline towards later-stage clinical development and commercialization. This move is expected to bolster the company's transition to a commercial-stag…

Leadership Shake-Up Sends Fiserv Shares Lower as CEO Departs for Truist

Leadership Shake-Up Sends Fiserv Shares Lower as CEO Departs for Truist

Fiserv Inc. shares fell about 7% after CEO Mike Lyons announced he is leaving to assume the CEO role at Truist Financial Corporation. The payments and financial-technology firm appointed Takis Georgakopoulos as CEO effective immediately. Fiserv also reaffirmed its full-year 2026 outlook, maintaining expectations for modest organic revenue growth an…

Nvidia Moves to Issue at Least $20 Billion of Investment-Grade Debt

Nvidia Moves to Issue at Least $20 Billion of Investment-Grade Debt

Nvidia Corp. is preparing an investment-grade bond offering intended to raise a minimum of $20 billion. The sale spans seven maturities between two and 30 years, with the longest-dated tranche marketed around 0.9 percentage points over Treasuries. Proceeds are slated for general corporate purposes, including repayment and refinancing of existing no…